Serenno Medical, developer of medical devices for patient monitoring in a hospital setting, announced that Elcam Medical, a leading producer of medical devices, has invested $1.5 million in the Company and will also manufacture Sentinel, Serenno’s urine output and intra-abdominal pressure digital monitoring device for the detection of acute kidney injury (AKI). Elcam Medical join existing investors Alon Medtech and serial medical device inventor, entrepreneur, and investor, Dr. Shimon Eckhouse.
The partnership combines Serenno’s unique solution with Elcam’s superior manufacturing experience to deliver high-quality products at a competitive price, that will enable the use of Sentinel in a variety of hospital environments.
Continuous kidney function assessment allows the early detection of AKI, a common condition in hospitalized patients that significantly increases the risk of mortality during and after hospitalization. Accurate measurement of urine output (UO) is clinically accepted as the best method for monitoring changes in kidney function. However, UO is currently monitored intermittently and manually by ICU staff, therefore acute changes in urine flow are difficult to detect. Thus, kidney injury is often detected relatively late, sometimes after it is impossible to prevent further progression.
Sentinel offers a simple and cost-effective solution for the precise, continuous measurement of urine volume and flow rate in real-time. The system promotes early detection of kidney injury, while there is still time to intervene and prevent further damage. It aims to automatically and accurately detect small changes in kidney function, allowing remote detection by the medical staff, reducing both patient and caregiver risk.
Tomer Lark, Co-Founder, and CEO, Serenno said: “The investment by Elcam Medical is a strong endorsement, and will allow us to swiftly move toward commercialization of our device. Elcam’s world-class production capabilities and experience will enable mass production and increased market access of Sentinel. Our plan is to begin deployment of the devices in several US hospitals towards the end of 2021, in the hope to eventually reduce kidney failure risk for every patient at ICUs.”
Dr. Shimon Eckhouse, Chairman, Serenno added: “We are pleased with Elcam’s investment, which marks the first commitment in Serenno’s larger planned current financial round. This partnership with Elcam is an excellent indication of the high degree of innovation and the significance of Serenno’s solution for the advancement of monitoring technologies. We are confident that Elcam’s leadership position in the global point-of-care market will play a critical role in bringing Serenno’s exciting technology to ICUs and patients around the world.”
Igal Kohn, CEO, Elcam Medical said: “Our investment in Serenno and the establishment of a production line for its device is aligned with Elcam’s strategy to cooperate with promising Israeli startups to deliver products with added value for the patient. Elcam Medical has joined Serenno as a board member and we look forward to taking part in the Company’s continued successes.”
